Literature DB >> 28679752

Simian Immunodeficiency Virus SIVmac239, but Not SIVmac316, Binds and Utilizes Human CD4 More Efficiently than Rhesus CD4.

Christoph H Fellinger1, Matthew R Gardner1, Charles C Bailey2, Michael Farzan3.   

Abstract

Rhesus macaques are used to model human immunodeficiency virus type 1 (HIV-1) infections, but they are not natural hosts of HIV-1 or any simian immunodeficiency virus (SIV). Rather, they became infected with SIV through cross-species transfer from sooty mangabeys in captivity. It has been shown that HIV-1 utilizes rhesus CD4 less efficiently than human CD4. However, the relative ability of SIV envelope glycoproteins to bind or utilize these CD4 orthologs has not been reported. Here we show that several SIV isolates, including SIVmac239, are more efficiently neutralized by human CD4-Ig (huCD4-Ig) than by the same molecule bearing rhesus CD4 domains 1 and 2 (rhCD4-Ig). An I39N mutation in CD4 domain 1, present in human and sooty mangabey CD4 orthologs, largely restored rhCD4-Ig neutralization of SIVmac239 and other SIV isolates. We further observed that SIVmac316, a derivative of SIVmac239, bound to and was neutralized by huCD4-Ig and rhCD4-Ig with nearly identical efficiencies. Introduction of two SIVmac316 CD4-binding site residues (G382R and H442Y) into the SIVmac239 envelope glycoprotein (Env) markedly increased its neutralization sensitivity to rhesus CD4-Ig without altering neutralization by human CD4-Ig, SIV neutralizing antibodies, or sera from SIV-infected macaques. These changes also allowed SIVmac239 Env to bind rhCD4-Ig more efficiently than huCD4-Ig. The variant with G382R and H442Y (G382R/H442Y variant) also infected cells expressing rhesus CD4 with markedly greater efficiency than did unaltered SIVmac239 Env. We propose that infections of rhesus macaques with SIVmac239 G382R/H442Y might better model some aspects of human infections.IMPORTANCE Rhesus macaque infection with simian immunodeficiency virus (SIV) has served as an important model of human HIV-1 infection. However, differences between this model and the human case have complicated the development of vaccines and therapies. Here we report the surprising observation that SIVmac239, a commonly used model virus, more efficiently utilizes human CD4 than the CD4 of rhesus macaques, whereas the closely related virus SIVmac316 uses both CD4 orthologs equally well. We used this insight to generate a form of SIVmac239 envelope glycoprotein (Env) that utilized rhesus CD4 more efficiently, while retaining its resistance to antibodies and sera from infected macaques. This Env can be used to make the rhesus model more similar in some ways to human infection, for example by facilitating infection of cells with low levels of CD4. This property may be especially important to efforts to eradicate latently infected cells.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CD4; SIVmac239; SIVmac316; human immunodeficiency virus; rhesus macaques; simian immunodeficiency virus

Mesh:

Substances:

Year:  2017        PMID: 28679752      PMCID: PMC5571245          DOI: 10.1128/JVI.00847-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

2.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.

Authors:  M Farzan; T Mirzabekov; P Kolchinsky; R Wyatt; M Cayabyab; N P Gerard; C Gerard; J Sodroski; H Choe
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

Review 4.  Mechanisms of HIV-1 neurotropism.

Authors:  Rebecca Dunfee; Elaine R Thomas; Paul R Gorry; Jianbin Wang; Petronela Ancuta; Dana Gabuzda
Journal:  Curr HIV Res       Date:  2006-07       Impact factor: 1.581

5.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Complex determinants of macrophage tropism in env of simian immunodeficiency virus.

Authors:  K Mori; D J Ringler; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  Macrophage-tropic variants of SIV are associated with specific AIDS-related lesions but are not essential for the development of AIDS.

Authors:  R C Desrosiers; A Hansen-Moosa; K Mori; D P Bouvier; N W King; M D Daniel; D J Ringler
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

8.  Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.

Authors:  Hui Li; Shuyi Wang; Rui Kong; Wenge Ding; Fang-Hua Lee; Zahra Parker; Eunlim Kim; Gerald H Learn; Paul Hahn; Ben Policicchio; Egidio Brocca-Cofano; Claire Deleage; Xingpei Hao; Gwo-Yu Chuang; Jason Gorman; Matthew Gardner; Mark G Lewis; Theodora Hatziioannou; Sampa Santra; Cristian Apetrei; Ivona Pandrea; S Munir Alam; Hua-Xin Liao; Xiaoying Shen; Georgia D Tomaras; Michael Farzan; Elena Chertova; Brandon F Keele; Jacob D Estes; Jeffrey D Lifson; Robert W Doms; David C Montefiori; Barton F Haynes; Joseph G Sodroski; Peter D Kwong; Beatrice H Hahn; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 12.779

9.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Authors:  Matthew R Gardner; Lisa M Kattenhorn; Hema R Kondur; Markus von Schaewen; Tatyana Dorfman; Jessica J Chiang; Kevin G Haworth; Julie M Decker; Michael D Alpert; Charles C Bailey; Ernest S Neale; Christoph H Fellinger; Vinita R Joshi; Sebastian P Fuchs; Jose M Martinez-Navio; Brian D Quinlan; Annie Y Yao; Hugo Mouquet; Jason Gorman; Baoshan Zhang; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton; Peter D Kwong; Michael Piatak; Jeffrey D Lifson; Guangping Gao; Ronald C Desrosiers; David T Evans; Beatrice H Hahn; Alexander Ploss; Paula M Cannon; Michael S Seaman; Michael Farzan
Journal:  Nature       Date:  2015-02-18       Impact factor: 49.962

10.  AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity.

Authors:  Sebastian P Fuchs; José M Martinez-Navio; Michael Piatak; Jeffrey D Lifson; Guangping Gao; Ronald C Desrosiers
Journal:  PLoS Pathog       Date:  2015-08-06       Impact factor: 6.823

View more
  3 in total

1.  AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges.

Authors:  Matthew R Gardner; Christoph H Fellinger; Lisa M Kattenhorn; Meredith E Davis-Gardner; Jesse A Weber; Barnett Alfant; Amber S Zhou; Neha R Prasad; Hema R Kondur; Wendy A Newton; Kimberly L Weisgrau; Eva G Rakasz; Jeffrey D Lifson; Guangping Gao; Nancy Schultz-Darken; Michael Farzan
Journal:  Sci Transl Med       Date:  2019-07-24       Impact factor: 17.956

2.  eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody.

Authors:  Christoph H Fellinger; Matthew R Gardner; Jesse A Weber; Barnett Alfant; Amber S Zhou; Michael Farzan
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

3.  Potent suppression of HIV-1 cell attachment by Kudzu root extract.

Authors:  S Mediouni; J A Jablonski; S Tsuda; A Richard; C Kessing; M V Andrade; A Biswas; Y Even; T Tellinghuisen; H Choe; M Cameron; M Stevenson; S T Valente
Journal:  Retrovirology       Date:  2018-09-20       Impact factor: 4.602

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.